Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Non Operating Income (2018 - 2023)

UroGen Pharma's Non Operating Income history spans 5 years, with the latest figure at -$715000.0 for Q4 2023.

  • For Q4 2023, Non Operating Income fell 79.65% year-over-year to -$715000.0; the TTM value through Dec 2023 reached -$689000.0, down 161.98%, while the annual FY2025 figure was $605000.0, 176.26% up from the prior year.
  • Non Operating Income reached -$715000.0 in Q4 2023 per URGN's latest filing, down from $71000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $989000.0 in Q1 2019 to a low of -$715000.0 in Q4 2023.
  • Average Non Operating Income over 4 years is -$8923.1, with a median of -$15000.0 recorded in 2023.
  • The largest YoY upside for Non Operating Income was 331.25% in 2022 against a maximum downside of 416.88% in 2022.
  • A 4-year view of Non Operating Income shows it stood at $989000.0 in 2019, then tumbled by 107.79% to -$77000.0 in 2021, then crashed by 416.88% to -$398000.0 in 2022, then crashed by 79.65% to -$715000.0 in 2023.
  • Per Business Quant, the three most recent readings for URGN's Non Operating Income are -$715000.0 (Q4 2023), $71000.0 (Q3 2023), and -$30000.0 (Q2 2023).